Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms

Betina Yanez; Laura C. Bouchard; David Cella; Jeffrey A. Sosman; Sheetal M. Kircher; Nisha A. Mohindra; Massimo Cristofanilli; Frank J. Penedo

doi:10.1002/cncr.32030

Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms

Betina Yanez, Laura C. Bouchard, David Cella, Jeffrey A. Sosman, Sheetal M. Kircher, Nisha A. Mohindra, Massimo Cristofanilli, Frank J. Penedo

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	2338-2344
Number of pages	7
Journal	cancer
Volume	125
Issue number	14
DOIs	https://doi.org/10.1002/cncr.32030
State	Published - Jul 15 2019

Funding

We acknowledge Dr. DerShung Yang at BrightOutcome, Inc, for his assistance with technology development and Ms. Diana Buitrago for her assistance with project management. Funding for the projects reported in this publication were provided by the following agencies: the Agency for Healthcare Research and Quality (grant K12HS023011 to David Cella, principal investigator, and Betina Yanez [grant R34AT009447], career development recipient); the National Cancer Institute (grant R21CA226671 to Betina Yanez, principal investigator); the American Cancer Society, the Melanoma Research Alliance, and Bristol-Myers Squibb (grant MRAP-18-112-01-CPHPS to Betina Yanez, principal investigator); and the National Center for Complementary and Integrative Health. Funding for this research was also supported by Northwestern University Robert H. Lurie Comprehensive Cancer Center development funds (NCI CCSG P30 CA060553) provided to Frank Penedo.

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.32030

Cite this

@article{3e275efa567e459b81e64a4e8b39d15d,

title = "Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms",

author = "Betina Yanez and Bouchard, {Laura C.} and David Cella and Sosman, {Jeffrey A.} and Kircher, {Sheetal M.} and Mohindra, {Nisha A.} and Massimo Cristofanilli and Penedo, {Frank J.}",

note = "Funding Information: We acknowledge Dr. DerShung Yang at BrightOutcome, Inc, for his assistance with technology development and Ms. Diana Buitrago for her assistance with project management. Funding Information: Funding for the projects reported in this publication were provided by the following agencies: the Agency for Healthcare Research and Quality (grant K12HS023011 to David Cella, principal investigator, and Betina Yanez [grant R34AT009447], career development recipient); the National Cancer Institute (grant R21CA226671 to Betina Yanez, principal investigator); the American Cancer Society, the Melanoma Research Alliance, and Bristol-Myers Squibb (grant MRAP-18-112-01-CPHPS to Betina Yanez, principal investigator); and the National Center for Complementary and Integrative Health. Funding for this research was also supported by Northwestern University Robert H. Lurie Comprehensive Cancer Center development funds (NCI CCSG P30 CA060553) provided to Frank Penedo.",

year = "2019",

month = jul,

day = "15",

doi = "10.1002/cncr.32030",

language = "English (US)",

volume = "125",

pages = "2338--2344",

journal = "cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "14",

}

TY - JOUR

T1 - Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy

T2 - The OncoTool and OncoPRO platforms

AU - Yanez, Betina

AU - Bouchard, Laura C.

AU - Cella, David

AU - Sosman, Jeffrey A.

AU - Kircher, Sheetal M.

AU - Mohindra, Nisha A.

AU - Cristofanilli, Massimo

AU - Penedo, Frank J.

N1 - Funding Information: We acknowledge Dr. DerShung Yang at BrightOutcome, Inc, for his assistance with technology development and Ms. Diana Buitrago for her assistance with project management. Funding Information: Funding for the projects reported in this publication were provided by the following agencies: the Agency for Healthcare Research and Quality (grant K12HS023011 to David Cella, principal investigator, and Betina Yanez [grant R34AT009447], career development recipient); the National Cancer Institute (grant R21CA226671 to Betina Yanez, principal investigator); the American Cancer Society, the Melanoma Research Alliance, and Bristol-Myers Squibb (grant MRAP-18-112-01-CPHPS to Betina Yanez, principal investigator); and the National Center for Complementary and Integrative Health. Funding for this research was also supported by Northwestern University Robert H. Lurie Comprehensive Cancer Center development funds (NCI CCSG P30 CA060553) provided to Frank Penedo.

PY - 2019/7/15

Y1 - 2019/7/15

UR - http://www.scopus.com/inward/record.url?scp=85065190979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065190979&partnerID=8YFLogxK

U2 - 10.1002/cncr.32030

DO - 10.1002/cncr.32030

M3 - Article

C2 - 31034599

AN - SCOPUS:85065190979

SN - 0008-543X

VL - 125

SP - 2338

EP - 2344

JO - cancer

JF - cancer

IS - 14

ER -

Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this